TheranosticTrials.org

Clinical Trial · NCT01583842

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

Overview

This is a pilot study with the primary purpose to describe organ dosimetry and acute toxicities using no carrier added and carrier added 124I-MIBG PET/CT in patients with neuroblastoma (NB). Eligible patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG. After all eligibility criteria are met, patients will receive a diagnostic imaging dose of 124I-MIBG followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5. Subsequent, planned therapeutic administration of 131I-MIBG will occur between Days 7 to 21, as specified by the patient's therapeutic MIBG protocol. An optional single follow up 124I-MIBG PET-CT scan will be done to assess tumor sites 6 weeks after the patient has their MIBG therapy.

Sponsor

University of California, San Francisco

Phase

Early Phase 1

Contacts

Youngho Seo, PhD (PRINCIPAL_INVESTIGATOR)

Jose Miguel Hernandez-Pampaloni, MD, PhD (PRINCIPAL_INVESTIGATOR)

Katherine Matthay, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01583842

Drug / Compound

MIBG

Isotope(s):
Target(s):
  • NET
Ligand Class: Small Molecules

MIBG

Isotope(s):
Target(s):
  • NET
Ligand Class: Small Molecules

Eligibility

Inclusion

  • All post-menarchal females must have a negative beta-Human Chorionic Gonadotropin (hCG) within 2 weeks prior to receiving the dose of 124I-MIBG. Males and females of childbearing potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus.Imaging only cohort:\- Patients with high-risk neuroblastoma are eligible at any time (during initial treatment or during treatment of relapsed/refractory disease) as long as they meet the requirements.
  • Patients must meet eligibility criteria for 131I-MIBG therapy in order to participate in the dosimetry portion.
  • 123I-MIBG Uptake: Patients must have MIBG evaluable disease which is defined as evidence of uptake into tumor at one site within 4 weeks prior to entry on study and subsequent to any intervening therapy.
  • Refractory disease (i.e. less than a partial response to frontline therapy, including a minimum of 4 cycles of chemotherapy). No biopsy is required for eligibility for this study.
  • Recurrent/progressive disease at any time. Biopsy is not required, even if there is a partial response to intervening therapy or
  • Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamine metabolites.

Exclusion

  • Pregnancy or lactating with the intent of breast feeding.
  • Patients who require general anesthesia for MIBG imaging studies.